Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
暂无分享,去创建一个
E. Philip | C. Bergerot | P. Bergerot | J. Hsu | S. Salgia | N. Salgia | Z. Zengin | A. Chehrazi-Raffle | J. Malhotra | Daniela V. Castro | Sandy Liu | Ameish Govindarajan | Meghan Salgia | Luis Meza | Abhishek Tripathi | Tanya Dorff | Sumanta Pal
[1] W. Linehan,et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. , 2021, The New England journal of medicine.
[2] Jason Zhu,et al. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer , 2020, The Prostate.
[3] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[4] M. Galsky,et al. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results , 2020, Cancer.
[5] B. Ramaswamy,et al. Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions. , 2019, JCO precision oncology.
[6] B. Ramaswamy,et al. Metastatic breast cancer patient perceptions of somatic tumor genomic testing , 2019, BMC Cancer.
[7] H. Williams,et al. Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes. , 2019, Urologic oncology.
[8] W. Chung,et al. Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies , 2019, Genetics in Medicine.
[9] N. Rothman,et al. Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. , 2019, European urology.
[10] Jonathan M Marron,et al. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience , 2016, Pediatric blood & cancer.
[11] Kelvin K. W. Chan,et al. Genomic testing in cancer: Patient knowledge, attitudes, and expectations , 2014, Cancer.
[12] D. Flum,et al. Shared decision-making for cancer care among racial and ethnic minorities: a systematic review. , 2013, American journal of public health.
[13] Barbara A Koenig,et al. Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. , 2011, Mayo Clinic proceedings.